Sunday, July 25, 2021
HomeClinical ResearchCoronavirus treatment: List of Vaccines and drugs in the pipeline for COVID-19

Coronavirus treatment: List of Vaccines and drugs in the pipeline for COVID-19

As the number of confirmed cases of COVID-19 continues to rise, healthcare researchers around the world are working tirelessly to discover new life-saving innovations in medicine.

Here are some companies and institutions developing new treatment options for COVID-19

Vaccine Company name Type of Vaccine Phase of study Study link
mRNA1273  (2019-nCoV Vaccine)   Emory University in Atlanta RNA Phase I https://clinicaltrials.gov/ct2/show/NCT04283461
Ad5-nCoV Cansino Bio  Non replicating viral vector Phase I https://www.precisionvaccinations.com/vaccines/ad5-ncov-covid-19-vacci
  chadox1 ncov19 University of Oxford Non replicating viral vector Phase I/II https://www.clinicaltrials.gov/ct2/show/NCT04324606
LVSMENP-DC Shenzhen Geno immune medical institute lentiviral Phase I/II https://clinicaltrials.gov/ct2/show/NCT04276896
BCG vaccines (Bacille Calmette-Guérin)   Murdoch Childrens Research Institute. Live Attenuated virus Phase II/III https://clinicaltrials.gov/ct2/show/NCT04327206
     Drug Company name Mechanism of action Phase of study Study link
Sylvant
(Siltuximab)
EUSA Pharma interleukin (IL)-6 inhibitor Observational study   https://www.clinicaltrials.gov/ct2/show/NCT04322188  
Gimsilumab Roivant monoclonal antibody targeting GM-CSF Phase I https://clinicaltrials.gov/ct2/show/NCT04351243?intr=Gimsilumab&draw=2&rank=1
Losartan Univ. of Minnesota ANGIOTENSIN TYPE 1 RECEPTOR inhibitor Phase II https://clinicaltrials.gov/ct2/show/NCT04312009
AiRuiKa (camrelizumab) Southeast Univ China PD-1 inhibitor Phase II https://clinicaltrials.gov/ct2/show/NCT04268537
Fingolimod    First Affiliated Hospital of Fujian Medical University Sphingosine 1-phosphate receptor modulator Phase II https://clinicaltrials.gov/ct2/show/NCT04280588
SNG001 Synairgen IFN-beta 1a Sphingosine phosphate receptor modulator Phase II https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB
Kaletra AbbVie’s HIV protease. Failed trial https://news.abbvie.com/news/press-releases/abbvie-partnering-with-global-authorities-to-determine-efficacy-hiv-drug-in-treating-covid-19.htm
Ganovo + Ritonavir Ascletis HCV NS3/4A protease inhibitor. Phase IV https://clinicaltrials.gov/ct2/show/NCT04345276?
Actemra (Tocilizumab) Roche IL-6 receptors inhibitor Phase III https://clinicaltrials.gov/ct2/show/NCT04351152?intr=Lenzilumab&draw=2&rank=2  
CD24Fc Oncoimmune  modulate immune  responses Phase III https://clinicaltrials.gov/ct2/show/NCT04317040?intr=CD24Fc&draw=2&rank=2
Prezcobix Shanghai Public health clinical centre HIV protease inhibitor Phase III https://clinicaltrials.gov/ct2/show/NCT04252274
Colchine The Montreal Heart Institute (MHI) Research Centre Tubulin Disruption Phase III https://clinicaltrials.gov/ct2/show/NCT04322682
Kevzara (sarilumab) Sanofi and Regeneron IL-6 receptor Phase 2/3 https://clinicaltrials.gov/ct2/show/NCT04315298
 Hydroxychloroquine University of Minnesota ACE2 inhibitor Phase II/III https://clinicaltrials.gov/ct2/show/NCT04308668  
Avigan FUJIFILM RNA polymerase inhibitor Phase III https://www.fujifilm.com/jp/en/news/hq/3211
Avastin (Bevacizumab)  Qilu Hospital of Shandong University VEGF inhibitor Phase 2/3   https://clinicaltrials.gov/ct2/show/NCT04275414
Remdesivir Gilead Adenosine analouge Phase III https://clinicaltrials.gov/ct2/show/NCT04292730?intr=remdesivir&lead=Gilead&draw=2&rank=3
Leronlimab (PRO140) CytoDyn CCR5antagonist Phase 2b/3 https://clinicaltrials.gov/ct2/show/NCT04347239?intr=Leronlimab&draw=2&rank=3
Aviptadil NeuroRx IL-6 inhibitor Phase II https://clinicaltrials.gov/ct2/show/NCT04311697

Lenzilumab

Humanigen
Anti GM-CSF
Phase III



https://clinicaltrials.gov/ct2/show/NCT04351152?intr=Lenzilumab&draw=2&rank=2

Mesenchymal stem cells
various instituteTissue regenerationPhase I
https://link.springer.com/article/10.1007/s12015-020-09973-w/tables/1
- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

fourteen − 9 =

- Advertisment -

Most Popular